GSK plc (GSK)
| Market Cap | 77.91B |
| Revenue (ttm) | 39.41B |
| Net Income (ttm) | 5.75B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.77 |
| PE Ratio | 13.82 |
| Forward PE | 10.32 |
| Dividend | $1.50 (3.94%) |
| Ex-Dividend Date | May 16, 2024 |
| Volume | 3,147,782 |
| Open | 38.11 |
| Previous Close | 38.38 |
| Day's Range | 37.81 - 38.32 |
| 52-Week Range | 33.67 - 45.93 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 48.00 (+25.62%) |
| Earnings Date | Jul 31, 2024 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is $48.0, which is an increase of 25.62% from the latest price.
News
GSK stock falls more at London open following RSV vaccination news
GSK's London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated aga...
GSK slides 6% after US CDC narrows scope of RSV shots
GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending...
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinate...
US advisers to consider RSV shots as GSK looks to keep market lead
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles riva...
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease
OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership wil...
US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--US FDA approves expanded age indication for GSK's AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus. The agen...
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus vaccine on Friday in adults aged between 50 and 59, making it the first shot endorsed for that age ...
GSK Stock Dives After Judge Allows Zantac Cancer Lawsuits To Go Forward
American depositary receipts (ADRs) of GSK Plc (GSK) tumbled in intraday trading Monday after a Delaware court ruled that lawsuits claiming the drugmaker's discontinued heartburn treatment, Zantac, ca...
Is GSK stock a sell with 75,000 Zantac cases moving forward?
GSK plc (NYSE:GSK) faced a significant setback on June 3rd when its stock plunged by 8% following a Delaware judge's ruling allowing over 70,000 lawsuits against the company regarding its discontinued...
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
GSK shares plunged Monday after the Delaware State Court ruled that expert witnesses can present scientific evidence in the roughly 75,000 cases relating to the discontinued heartburn drug Zantac. The...
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer.
GSK shares tumble 10% after Zantac ruling
GSK shares dropped 10% after a ruling by the Delaware State Court that will allow jury trials in cases brought by cancer sufferers who say the heartburn drug Zantac caused their condition. GSK said it...
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to move forward
Shares in British drugmaker GSK dropped more than 9% on Monday after a Delaware judge allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward.
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
PHILADELPHIA--(BUSINESS WIRE)-- #ASCO24--Belantamab Mafodotin combo reduced the risk of disease progression or death by nearly 50% versus SOC combo in relapsed/refractory multiple myeloma.
GSK blood cancer drug nearly halves risk of death in late-stage trial
GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage s...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.
GSK says late-stage trials of potential blockbuster asthma drug met their goals
GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.
GSK's asthma drug shows promise in reducing severe attacks
GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday.
GSK faces whistleblower lawsuit over Zantac cancer risk
GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn...
GSK raises $1.5 bln from offloading Haleon stake at a discount
GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
GSK intends to sell its remaining stake in Haleon
British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for seri...
5 best blue chip stocks to invest in for sustainable gains in May – excluding Apple Inc. (AAPL)
Yesterday, the biggest company in the world in terms of market cap reported its latest earnings. But Apple Inc. is far from the only blue chip stock around.